AngioDynamics, Inc. reported $325M of revenue over the trailing twelve months, +8.2% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $325M (to Q1 2027). Net income: −$33M, trailing twelve months to Q1 2027. Free cash flow: $1.4M, trailing twelve months to Q1 2027. Operating margin: −11%, trailing twelve months to Q1 2027.

ANGOAngioDynamics, Inc.

Healthcare

$11.22+1.5% 1Y

$11.22

$9.7052 weeks$16.12

Latest close: below its 200-day averageOct 8, 2026what changed →

ANGO as reported

AngioDynamics, Inc. reported $325M of revenue over the trailing twelve months, +8.2% on the year before. 11 reported series are charted on this page, each one as filed.

$325M

Revenue, trailing twelve months · to Q1 2027 · +8.2% against the twelve months before

Net income: −$33M
Net income · +2.6% year on year · trailing twelve months to Q1 2027
Free cash flow: $1.4M
Free cash flow · −112% year on year · trailing twelve months to Q1 2027
Operating margin: −11%
Operating margin · trailing twelve months to Q1 2027

Details›

Every series Ryufin has for ANGO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$325M	+8.2%	Q1 2027
Net income	−$33M	+2.6%	Q1 2027
EPS	−$0.78	+0.00%	Q1 2027
Gross margin	56%	n/a	Q1 2027
Operating margin	−11%	n/a	Q1 2027
Net margin	−10%	n/a	Q1 2027
ROE	−19%	n/a	Q1 2027
ROA	−12%	n/a	Q1 2027
ROIC	−7.4%	n/a	Q4 2023 · 13 quarters behind
Free cash flow	$1.4M	−112%	Q1 2027
P/E	10.7	n/a	Q3 2020 · 26 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.